ClinicalTrials.gg
CompletedNCT00041925Updated Jul 15, 2005

Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures

A Phase 2/3 interventional study of CGT003 (E2F Duplex Decoy) in Peripheral Vascular Diseases, Arterial Occlusive Diseases and Ischemia, sponsored by Anesiva, Inc.. Completed at 123 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-07-15.

Sponsored by Anesiva, Inc. · Phase 2/3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 187 studies in Peripheral Vascular Diseases with a site in United States — 18 open to participants now, 23 under way, 2 of them phase 3. Peripheral Vascular Diseases · United States.

Enrollment
3rd of 158
1,400 · median 82
Started
2001
with 2 others
Phase 2/3
4 of 187
none open now
Registered
4th of 187
by date

Among the 187 studies in Peripheral Vascular Diseases with a site in United States, this one is the 3rd largest by enrollment of the 158 interventional ones that give a count, is one of 3 that started in 2001, is one of 4 in phase 2/3, and was the 4th registered.

Peripheral Vascular Diseases

443 studies on the registry are indexed under Peripheral Vascular Diseases; 44 are open to participants now.

Browse Peripheral Vascular Diseases studies →

Open to participants now

18 of the 187 studies in Peripheral Vascular Diseases with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 32 Peripheral Vascular Diseases studies recruiting now, 19 (59%) set no upper age limit and 4 (13%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Peripheral Vascular Diseases with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy of graft pretreatment with the E2F decoy, CGT003, as compared to placebo, on the occurrence of graft failure among patients who receive autogenous vein grafts to treat chronic critical limb ischemia; on the occurrence of clinically significant graft stenosis (more than or equal to 70%); and on the incidence of critical limb ischemia (e.g., gangrene, non-healing ischemic ulcers or ischemic rest pain).

Read the detailed description

Peripheral vascular disease manifested by narrowing of the peripheral arteries is one of the more common manifestations of atherosclerotic vascular disease. Complications such as claudication, rest pain, and impaired wound healing are frequent and may result in gangrene and amputation. Restoration of circulation to the lower extremities may be undertaken using a variety of techniques including angioplasty, stenting, and bypass grafting.

Approximately 99,000 infra-inguinal bypass procedures were performed in the U.S. in 1998. It is estimated that approximately 22% of all infra-inguinal bypass grafts will fail by 12 months. Graft failure rates have been estimated to increase to 40% at 12 months for patients receiving composite, cephalic or lesser saphenous (high-risk) vein grafts (Vascular Surgery Registry, Brigham and Women's Hospital). These primary graft failures are typically due to stenoses that result from neointimal hyperplasia, a pathological adaptation process that occurs in veins exposed to the arterial circulation. The consequences of graft failure are as significant as those of primary atherosclerotic disease and include ischemia and poor wound healing that may result in amputation. Since the long-term patency of venous grafts can be improved with treatment prior to frank occlusion, considerable efforts have been focused on the methods for the detection of grafts at high-risk for failure. Duplex ultrasonography has been determined to be a sensitive screening test for the early detection of failing grafts. Peak systolic velocity (PSV), as measured by duplex ultrasound, has been shown to be a sensitive marker for low flow, and wave form analysis has permitted the identification of areas of stenosis in the vein under study. Management of patients who have undergone infra-inguinal bypass therefore includes routine surveillance with duplex ultrasound and the immediate correction of significant (more than or equal to 70%) graft stenoses.

03

Conditions studied

  • Peripheral Vascular Diseases
  • Arterial Occlusive Diseases
  • Ischemia
  • Graft Occlusion, Vascular
  • Hyperplasia

Keywords

  • atherosclerotic vascular disease
  • chronic critical limb ischemia
  • neointimal hyperplasia
  • peripheral vein bypass
  • infra-inguinal bypass grafting surgery
  • graft stenosis
  • occluded grafts
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

PATIENTS MUST:

  • Be scheduled to undergo infra-inguinal bypass grafting surgery using excised autogenous vein for Chronic Critical Limb Ischemia (i.e., rest pain, non-healing ulceration or gangrene). For patients presenting with rest pain as the only manifestation of CCLI, must have the diagnosis confirmed by at least one of the following,: i.) an ankle pressure of \< 50 mmHg (or ABI \<0.4), ii.) a toe pressure \< 30 mmHg, iii.) a reduced TCPO2 \< 30 mmHg, or iv.) a severely ischemic or flat line transtarsal pulse volume recording (i.e., Category V).
  • Be males or females of at least 18 years old.
  • Have agreed to participate voluntarily and signed and dated an IRB-approved, Patient form.
  • Have a documented negative serum pregnancy test for all women of .
  • Be using an acceptable method of if of .
  • Note: Patients undergoing operations to replace previously occluded grafts that involve placement of an entirely new bypass graft ARE eligible for this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Single group
Masking
Double
Enrollment
1,400 participants

Interventions

  • DrugCGT003 (E2F Duplex Decoy)
06

Study locations

123 sites
  • The Kirklin Clinic
    Birmingham, Alabama 35233, United States
  • University Hospital
    Birmingham, Alabama 35294, United States
  • Mobile Infirmary Medical Center
    Mobile, Alabama 36607, United States
  • Vascular Specialists of Mobile, PC
    Mobile, Alabama 36607, United States
  • Springhill Memorial Hopsital
    Mobile, Alabama 36608, United States
  • Tucson Heart Hospital
    Tucson, Arizona 85704, United States
  • University Medical Center
    Tucson, Arizona 85724, United States
  • Northwest Hospital
    Tucson, Arizona 85741, United States
  • Tucson Vascular Surgery
    Tucson, Arizona 85741, United States
  • Southern Arizona Vascular Institute
    Tucson, Arizona 85745, United States
  • St. Mary's Hospital
    Tucson, Arizona 85745, United States
  • Baptist Health
    Little Rock, Arkansas 72205, United States
  • Central Arkansas Veterans Healthcare System
    Little Rock, Arkansas 72205, United States
  • University of Arkansas for Medical Sciences Hospital
    Little Rock, Arkansas 72205, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • VA Palo Alto Health Care System
    Palo Alto, California 94304, United States
  • Kaiser Permanente - San Diego, SCPMG, Department of Surgery
    San Diego, California 92120, United States
  • Kaiser Permanente Franklin Medical Center
    Denver, Colorado 80205, United States
  • Exempla Healthcare Saint Joseph Hospital
    Denver, Colorado 80218, United States
  • Hartford Hospital
    Hartford, Connecticut 06102, United States
  • Washington Hospital Center, Center for Vascular Care
    Washington, District of Columbia 20010, United States
  • Malcom Randall VA Medical Center
    Gainesville, Florida 32608, United States
  • Shands Hospital at the University of Florida
    Gainesville, Florida 32610, United States
  • Samson Showalter Vascular Specialists
    Sarasota, Florida 34233, United States
  • Clinical Research Center
    Sarasota, Florida 34239, United States
  • Sarasota Memorial Hospital
    Sarasota, Florida 34239, United States
  • Vascular & Surgery Assoc.
    Sarasota, Florida 34239, United States
  • Tampa General Hospital
    Tampa, Florida 33601, United States
  • Emory University School of Medicine Hospital
    Atlanta, Georgia 30322, United States
  • Saint Joseph's Hospital of Atlanta
    Atlanta, Georgia 30342, United States
  • Vascular Institute of Georgia
    Atlanta, Georgia 30342, United States
  • Atlanta VA Medical Center
    Decatur, Georgia 30033, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Methodist Hospital
    Indianapolis, Indiana 46202, United States
  • Veteran's Affairs Medical Center
    Indianapolis, Indiana 46202, United States
  • Our Lady of the Lake Regional Medical Center
    Baton Rouge, Louisiana 70808, United States
  • Maine Medical Center
    Portland, Maine 04102, United States
  • University of Maryland Hospital
    Baltimore, Maryland 21201, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • New England Medical Center Hospital
    Boston, Massachusetts 02111, United States
  • Brigham & Women's Hospital
    Boston, Massachusetts 02115, United States
  • Beth-Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Dept. of Surgery at Harvard Medical Faculty Physicians
    Boston, Massachusetts 02215, United States
  • William Beaumont Hospital
    Royal Oak, Michigan 48073, United States
  • O.W. Brown, M.D.
    Southfield, Michigan 48075, United States
  • Lakeland Hospital
    St. Joseph, Michigan 49085, United States
  • Steven D. Rimar, M.D.
    Troy, Michigan 48098, United States
  • St. Mary's Hospital
    Rochester, Minnesota 55902, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University School of Medicine
    St. Louis, Missouri 63110, United States
  • Methodist Hospital
    Omaha, Nebraska 68114, United States
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Dr. Randy Shafrtiz, Clinical Office
    Holmdel, New Jersey 07733, United States
  • Morristown Memorial Hospital
    Morristown, New Jersey 07960, United States
  • Surgical Specialists of NJ, Morris Vascular Center
    Morristown, New Jersey 07960, United States
  • Robert Wood Johnson University Hospital
    New Brunswick, New Jersey 08903, United States
  • Umdnj-Rwjms
    New Brunswick, New Jersey 08903, United States
  • UMDNJ - New Jersey Medical School, University Hospital
    Newark, New Jersey, United States
  • Albany Medical Center
    Albany, New York 12208, United States
  • Montefiore Hospital
    Bronx, New York 10467, United States
  • Kings County Hospital
    Brooklyn, New York 11203, United States
  • SUNY Downstate University Hospital of Brooklyn and Medical School
    Brooklyn, New York 11203, United States
  • Maimonides Medical Center
    Brooklyn, New York 11219, United States
  • New York Presbyterian Hospital, Weill Medical College of Cornell University
    New York, New York 10021, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • Columbia Presbyterian Medical Center
    New York, New York 10032, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Gaston Memorial Hospital
    Gastonia, North Carolina 28054, United States
  • Pitt County Memorial Hospital
    Greenville, North Carolina 27834, United States
  • Department of Surgery, Division of Vascular Surgery, East Carolina University
    Greenville, North Carolina 27858, United States
  • Wake Forest University School of Medicine
    Winston Salem, North Carolina 27157, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Flower Hospital
    Sylvania, Ohio 43560, United States
  • Jobst Vascular Center
    Toledo, Ohio 43606, United States
  • The Toledo Hospital
    Toledo, Ohio 43606, United States
  • Oregon Health Sciences University
    Portland, Oregon 97201, United States
  • Penn State College of Medicine
    Hershey, Pennsylvania 17033, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • Veterans Administration Healthcare System
    Pittsburgh, Pennsylvania 15240, United States
  • Robert Packer Hospital
    Sayre, Pennsylvania 18840, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02905, United States
  • Medical University of South Carolina Hospital
    Charleston, South Carolina 29425, United States
  • University of Tennessee Medical Center
    Knoxville, Tennessee 37920, United States
  • St. Thomas Medical
    Nashville, Tennessee 37205, United States
  • The Surgical Group, PLLC
    Nashville, Tennessee 37205, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • VAMC
    Houston, Texas 77030, United States
  • University Medical Center
    Lubbock, Texas 79415, United States
  • Texas Tech University Health Sciences Center
    Lubbock, Texas 79430, United States
  • Baptist Medical Center
    San Antonio, Texas 78205, United States
  • Peripheral Vascular Associates
    San Antonio, Texas 78215, United States
  • Northeast Baptist Hospital
    San Antonio, Texas 78217, United States
  • Peripheral Vascular Associates
    San Antonio, Texas 78217, United States
  • Pro-Research Group
    San Antonio, Texas 78224, United States
  • Southwest Texas Methodist Hospital
    San Antonio, Texas 78229, United States
  • University of Utah Hospital and Clinics
    Salt Lake City, Utah 84132, United States
  • Vascular and Transplant Specialists, Peripheral Vascular Laboratory
    Chesapeake, Virginia 23320, United States
  • Vascular and Transplant Specialsts, Peripheral and Vascular Laboratory
    Chesapeake, Virginia 23320, United States

Showing the first 100 of 123 sites across 2 countries. Choose a country and city above to see the rest.

07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2001 and a completion of Nov 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2002
First posted
Jul 22, 2002
Start
Nov 2001
Completion
Nov 2004
Last update
Jul 15, 2005
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Jul 15, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00041925
Lead sponsor
Anesiva, Inc.
First posted
Jul 22, 2002
Start date
Nov 2001
Completion
Nov 2004
Last update
Jul 15, 2005

Study contacts

Todd Lorenz, M.D.
study director · Anesiva, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2005. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion